immunova   Report issue

For profit Phase 3
Founded: New Canaan CT United States (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2017
NCT03388216
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Inmunova S.A.

Active Ingredients

Drugs in Phase 3 Trials (2)

inm004 (3 trials)

inm005 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diarrhea (Phase 3)

Hemolysis (Phase 3)

Hemolytic-Uremic Syndrome (Phase 3)

Kidney Diseases (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2